文献速递造血干细胞移植与细胞治疗白血病

DISCOVeRY-BMT中共享的移植物抗白血病次要组织相容性抗原

Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT.
PubMed 文献 · Blood Adv · 2023-01-01

本研究基于DISCOVeRY-BMT数据集3231对供受者,依据预测免疫原性、组织表达及供受者间共享程度,发现大量新型移植物抗白血病次要组织相容性抗原(GVL mHA)。验证了24个预测新型GVL mHA,在表达HLA-A*02:01、HLA-B*35:01和HLA-C*07:02的供受者中累积覆盖分别为98.8%、60.7%和78.9%。

要点

  • 基于预测免疫原性、组织表达和供受者共享程度,从DISCOVeRY-BMT数据集发现大量新型GVL mHA。
  • 验证24个新型GVL mHA,在表达HLA-A*02:01、HLA-B*35:01、HLA-C*07:02的供受者中累积覆盖98.8%、60.7%、78.9%。
  • 通过肽脉冲树突状细胞与T细胞共培养,确认一个新型mHA的免疫原性。

核心结论

  • 本工作表明,鉴定共享mHA是扩展mHA靶向免疫治疗的一种可行且有前景的技术。

研究设计与样本

  • 基于DISCOVeRY-BMT数据集3231对alloHCT供受者(DRP)的预测分析,结合质谱搜索和体外T细胞共培养验证。

主要发现

  • 预测mHA总数随HLA等位基因不同而变化,且mHA总数及各类mHA数量在受者基因组祖先组间显著不同。
  • 从预测mHA池中,鉴定出覆盖表达特定HLA等位基因100%DRP所需的最小GVL mHA集。
  • 使用质谱搜索3个常见HLA等位基因的高人群频率mHA。
  • 验证24个预测新型GVL mHA,在DISCOVeRY-BMT中表达HLA-A*02:01、HLA-B*35:01和HLA-C*07:02的DRP内累积覆盖率分别为98.8%、60.7%和78.9%。
  • 通过肽脉冲树突状细胞与T细胞共培养,确认一个示例新型mHA的免疫原性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell responses to minor histocompatibility antigens (mHAs) mediate graft-versus-leukemia (GVL) effects and graft-versus-host disease (GVHD) in allogeneic hematopoietic cell transplantation. Therapies that boost T-cell responses improve allogeneic hematopoietic cell transplant (alloHCT) efficacy but are limited by concurrent increases in the incidence and severity of GVHD. mHAs with expression restricted to hematopoietic tissue (GVL mHAs) are attractive targets for driving GVL without causing GVHD. Prior work to identify mHAs has focused on a small set of mHAs or population-level single-nucleotide polymorphism-association studies. We report the discovery of a large set of novel GVL mHAs based on predicted immunogenicity, tissue expression, and degree of sharing among donor-recipient pairs (DRPs) in the DISCOVeRY-BMT data set of 3231 alloHCT DRPs. The total number of predicted mHAs varied by HLA allele, and the total number and number of each class of mHA significantly differed by recipient genomic ancestry group. From the pool of predicted mHAs, we identified the smallest sets of GVL mHAs needed to cover 100% of DRPs with a given HLA allele. We used mass spectrometry to search for high-population frequency mHAs for 3 common HLA alleles. We validated 24 predicted novel GVL mHAs that are found cumulatively within 98.8%, 60.7%, and 78.9% of DRPs within DISCOVeRY-BMT that express HLA-A∗02:01, HLA-B∗35:01, and HLA-C∗07:02, respectively. We confirmed the immunogenicity of an example novel mHA via T-cell coculture with peptide-pulsed dendritic cells. This work demonstrates that the identification of shared mHAs is a feasible and promising technique for expanding mHA-targeting immunotherapeutics.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Olsen KS, Jadi O, Dexheimer S, et al. Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT. Blood Adv. 2023. PMID: 36477467. doi:10.1182/bloodadvances.2022008863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。